PROpel

REVIEW UroToday

PROpel

Search

The Efficacy of Olaparib in the PROfound Study – Fred Saad Details Fred Saad joins Alicia Morgans highlighting the efficacy of olaparib versus either abiraterone or enzalutamide, given a potential difference in the efficacy of NHA sequencing that he presented during a podium presentation at the American Urologic Association (AUA) Annual Meeting. The PROfound trial provided a rationale for United States Federal Drug Administration (FDA) approval of olaparib among...
Operationalizing Genomic Testing for Clinical Practice In Prostate Cancer - Jason Hafron Details Jason Hafron, MD, joins Alicia Morgans, MD, MPH in a conversation on operationalizing genomic testing in clinical practice, towards supporting the use of PARP inhibitors in the appropriate patients. Dr. Hafron emphasizes the key to this success begins with the implementation of clinical pathways. With streamlined accurate clinical pathways, we can speed up the process and provide care to the patie...
BRCA1/2 and Beyond - Molecular Diagnostic Testing and Treatments with PARP Inhibitors for mCRPC - Joaquin Mateo Details In May 2020, the United States Food and Drug Administration approved olaparib for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. Efficacy was investigated in the PROfound study, a pr...
Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Can Be Preselected to Maximize Benefit of Olaparib - Maha Hussain Details Reconsidering back-to-back AR-directed therapies: An interview with Maha Hussain, co-principal investigator of the PROfound study. Precision medicine and targeted therapy are possible in prostate cancer. Unmet needs have included more focused treatment and novel modes of action to counter resistance to hormonal and cytotoxic therapies. The PROfound study of the PARP inhibitor olaparib in heavily p...
Significantly Longer Duration of Overall Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - PROfound Study Journal Club - Zachary Klaassen and Christopher Wallis Details In this Journal Club, Zachary Klaassen and Christopher Wallis present on the recently published New England Journal of Medicine article Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer, data from the Phase 3 PROfound study. The primary outcome of the study was radiographic progression-free survival in cohort A, which was focused on BRCA1, BRCA2, and ATM mutant patients whi...
PARP Inhibitors Changing the Standard of Care for Treatment of Metastatic Prostate Cancer (mCRPC) - The PROfound Study Details Oliver Sartor joins Alicia Morgans to highlight the recently published PROfound Trial. A phase III trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal agent treatments. The PROfound trial was published in the New England Journal of Medicine...
PROfound Study - PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations - Maha Hussain Details Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design, it's intent, and specifications on how it was designed to arrive at the answer it was seeking. The PROfound Study, a Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cance...